Parkinson’s Disease

I beg to move,

That this House has considered care for Parkinson’s patients.

It is a pleasure to serve under your chairmanship, Mr Stuart. Like many colleagues across the House, I was proud to mark Parkinson’s Awareness Month last month. This annual observance is more than a symbolic gesture; it is a vital opportunity to raise awareness, challenge misconceptions, and advocate for the thousands of people across the UK who live with Parkinson’s every day. It is also a time to reflect on the progress we have made and, more importantly, the work that still lies ahead.

Parkinson’s is a condition that touches every corner of our society. It affects over 150,000 people in the UK, and that number is expected to rise to 172,000 by 2030. In my constituency of Colne Valley, there are an estimated 253 people living with Parkinson’s. These are not just statistics; they are our neighbours, our friends and our family members, and behind each number is a story of resilience, of daily challenges and of hope.

Parkinson’s is a progressive neurological condition. It is complex, degenerative and life-limiting. It affects movement, speech, cognition and mental health. There is no cure, and while treatments exist to manage symptoms, their effectiveness often diminishes over time. The condition manifests differently in each person: some may experience tremors and stiffness, while others struggle with depression—

Order. The sitting is suspended for 15 minutes for a Division in the House.

This variability makes Parkinson’s particularly challenging to diagnose, treat and manage. In West Yorkshire, the integrated care board is responsible for planning and delivering care for people with Parkinson’s. In 2023-24, spending on hospital admissions for Parkinson’s patients in our area rose by nearly 5%, with each admission costing more than £6,000. These figures underscore the urgent need for a more proactive, community-based approach to care—one that prevents hospitalisations and supports people to live well at home.

Today I want to highlight five critical areas in which we must act to improve care for people living with Parkinson’s: workforce shortages, support from diagnosis, timely medication, prescription charges, and access to innovation.

There is a severe shortage of neurologists and Parkinson’s specialists in the UK, and neurology services are meeting the 18-week referral target only about half of the time. The UK ranks near the bottom in Europe for the number of neurologists per capita. This shortage leads to delayed diagnoses, missed treatment windows, and a lack of access to essential multidisciplinary care. Only 44% of patients in England have access to an occupational therapist, 62% to a physiotherapist, and just 40% to a speech and language therapist. These professionals are not luxuries; they are essential to managing the condition and maintaining quality of life. Investing in this workforce is not only clinically necessary, but financially prudent.

One of my constituents is a strong advocate for the Parky charter. I understand that the Government cannot commit to everything that is in the charter, but does my hon. Friend agree that, at every fiscal event from now until the end of this Labour Government, they should seriously consider investing in these services and the professions that he talks about, or at the very least outline exactly what they are doing to provide support for people with neurological conditions?

I absolutely agree with my hon. Friend. That is crucial. We know the impact of Parkinson’s on individuals, and later I will mention two constituents I have been working with. I know the impact that it has on the community.

Parkinson’s costs the UK £3 billion annually. Much of that is due to unplanned hospital admissions and the lost productivity of unpaid carers. Too many people with Parkinson’s feel abandoned after receiving their diagnosis. Nearly a quarter report not being given adequate information or access to support services. That is totally unacceptable.

I defer to the hon. Member’s great wisdom on this matter, and he helpfully outlined the points that he intends to cover, but I want to add another aspect to the debate. The Government’s review of disability benefits may lead to pressure on people in receipt of personal independence payments, and it is poorly understood that people receive those payments to provide for adjustments that allow them to continue to work. Does he agree that the Government have an opportunity to learn from the system in Scotland? Scotland’s adult disability payment is a much more humane process, and it could support people in receipt of personal independence payments who have Parkinson’s, which is a fluctuating condition and may be missed.

We have to keep an open mind, look at what is being done in other places, countries and regions, and learn from that. We should take that on board and relate any changes in the future to good practice elsewhere. I thank the hon. Gentleman for the intervention.

A diagnosis of Parkinson’s is life-changing, and patients deserve immediate, comprehensive support. That is why Parkinson’s UK launched Parkinson’s Connect, which is a pioneering programme that enables healthcare professionals to refer newly diagnosed patients directly to a network of support. This includes access to specialist nurses, care advisers, local support groups and educational resources.

I want to look at things in a positive way for a moment. In my constituency, the local newspaper, the Ardrossan and Saltcoats Herald, highlights that the North Ayrshire table tennis club holds classes for people with Parkinson’s, and that the activity has been very well received. In 2024, a constituent of mine, Steve Morley from Stevenston, who took up table tennis to help with his symptoms after his Parkinson’s diagnosis, played at the World Masters in Rome. That is excellent. Does my hon. Friend agree that it is important to provide support for those with Parkinson’s who are keen to keep active?

I absolutely agree. This is not a case of placing people with Parkinson’s in the corner and providing them with medication; this is about helping them to lead full lives, improving their quality of life and aiding them to do what they want to do. I know from people I have met in the Parkinson’s community that that is exactly what they want to do, so I absolutely agree with my hon. Friend.

Early intervention can make a profound difference in how patients manage their condition and maintain their independence. For people with Parkinson’s, receiving medication on time—within 30 minutes of the prescribed schedule—is not a convenience; it is a necessity. Delays can lead to severe symptoms, including immobility, pain and, in extreme cases, life-threatening complications. However, more than half of hospitalised patients report problems receiving their medication on time.

A constituent of mine was diagnosed with Parkinson’s at the age of 61. Individual sufferers can experience the symptoms to varying degrees day by day, which brings into question the effectiveness of PIP assessments, the results of which can vary depending on when they are carried out. With medical assistance hard to come by, charities such as Parkinson’s UK and Cure Parkinson’s are vital to sufferers. Will the hon. Gentleman join me in thanking them and similar organisations for their support to these thousands of people across the country.

I absolutely agree—the role they play is vital in terms of supporting this community. To be truthful, the people I have met in those groups are inspirational, as is the work they do, so I thank them for that.

NHS England’s medicine safety improvement programme, running from 2024 to 2027, is a welcome step. It aims to ensure that time-critical medications are administered promptly in hospitals, but we must ensure that the programme is fully implemented and that its findings are acted upon across all NHS trusts. Timely medication is a basic right for Parkinson’s patients, and we must treat it as such. In England, people with Parkinson’s still face prescription charges, unlike in Wales, Scotland and Northern Ireland. These charges can be a significant burden, especially for working-age patients, who may already face reduced income due to their condition. Research shows that eliminating these charges could reduce hospital admissions and save the NHS money, but Parkinson’s remains absent from the list of conditions exempt from charges—a list that has not been meaningfully updated in more than 60 years. It is time for a review. We must ensure that no one is forced to choose between their health and their finances.

New treatments such as Produodopa, which was approved for NHS use in 2024, offer hope for those with severe symptoms. This medication could be life-changing for patients whose symptoms are not well managed by the existing treatments. However, due to staffing and funding constraints, many hospitals are unable to offer it. We must ensure that all patients who need innovative treatments, such as Produodopa, can access them, and that the NHS is equipped to adopt new therapies quickly and equitably. Innovation must not be a postcode lottery.

I will now turn briefly to my constituency. Since being elected, I have had the privilege of meeting Dr Chris Ryan and Mrs Liz Ryan MBE. Over a cup of tea in February, they shared their experiences and highlighted the urgent need for better Parkinson’s care in Kirklees. Liz, who received an MBE for her services to education, continues to be a pillar of our community despite her diagnosis. Together they have organised local events, including a Parkinson’s choir that brings joy and support to many.

We have five Back-Bench speakers. I will call the Front Benchers at 5.23 pm, so I will let hon. Members make a judgment on that. We will start with the ever-succinct and effective Ed Morello.

It is a pleasure to serve under your chairship, Mr Stuart—especially after that flattery. I congratulate the hon. Member for Colne Valley (Paul Davies) on securing this important debate.

Parkinson’s, as has been said, is the fastest growing neurological condition in the world. But behind every statistic is a family, a carer, a friend—someone whose daily life is shared by this illness. My constituents have written to me about their experiences of loved ones living with the disease. The stories they have shared are heart-breaking, with long waits for specialist care, difficulties accessing the right medication on time, and exhausting battles for financial and social support. I know I speak for many here when I say that we must do more.

Parkinson’s is a progressive condition, with more than 40 possible symptoms affecting movement, sleep, mental health, speech, eating and swallowing. Nearly half of those living with it will experience anxiety or depression, and more than half will develop psychotic symptoms as the condition progresses. Across the country, there are long waits for specialist care, a lack of multidisciplinary teams with Parkinson’s experience, and serious difficulties in accessing vital medication in a timely and consistent way.

We urgently need to overhaul the way that care is provided for people with Parkinson’s, particularly in rural areas. That begins with primary care. GPs are the front door to the NHS, yet we know that continuity of care is beginning to be eroded. That is why the Liberal Democrats are calling for everyone with a long-term condition such as Parkinson’s to have access to a named GP—someone who can understand their history and needs, and can advocate for timely referrals and co-ordinated care.

This is not just about funding more; it is about funding smarter. Primary and community care can prevent some hospital admissions and provide medication and essential support for those who cannot easily travel. That is especially important in rural areas like mine, where distance, isolation and sparse public transport already pose significant barriers to treatment.